Affinity Asset Advisors, LLC
- SEC CIK
- 0001773195
- Latest filing
- Aug 13, 2026
Holdings in Q2 2021
Holdings as of Jun 30, 2021, filed Aug 13, 2021. Long positions only; changes compare share counts with Q1 2021.
- Positions
- 62
- 0 vs. Q1 2021
- Portfolio value
- $209.9M
- +$5.92M (+2.9%) vs. Q1 2021
| Security | Class | Shares | Value | % of portfolio | Share change | Action | History |
|---|---|---|---|---|---|---|---|
| Medicus Sciences AcquisitionG5960S124 | *W EXP 02/12/202 | 33,333 | $34.0K | <0.1% | +33,333 | New | – |
| CVRXCVRx, Inc. | COM | 7,500 | $210.0K | 0.1% | +7,500 | New | History |
| Beauty Health Co88331L116 | EQUITY WRT | 45,000 | $288.0K | 0.1% | +45,000 | New | – |
| CTMXCytomX Therapeutics, Inc. | COM | 75,000 | $475.0K | 0.2% | +25,000+50.0% | Added | History |
| APLSApellis Pharmaceuticals, Inc. | COM | 10,000 | $632.0K | 0.3% | +10,000 | New | History |
| ITOSiTeos Therapeutics, Inc. | COM | 25,000 | $641.0K | 0.3% | +25,000 | New | History |
| Immatics N.V.N44445117 | *W EXP 07/01/202 | 190,000 | $654.0K | 0.3% | −10,000−5.0% | Reduced | – |
| HARPHarpoon Therapeutics, Inc. | COM | 50,000 | $694.0K | 0.3% | +30,000+150.0% | Added | History |
| GBTGlobal Blood Therapeutics, Inc. | COM | 20,000 | $700.0K | 0.3% | 00.0% | Unchanged | History |
| Achilles Therapeutics PLC00449L102 | SPONSORED ADS | 80,000 | $783.0K | 0.4% | +55,000+220.0% | Added | – |
| Chardan Healthcr Acqstn 2 Co15957T206 | UNIT 99/99/9999 | 75,000 | $819.0K | 0.4% | 00.0% | Unchanged | – |
| QSIQuantum-Si Inc | COM CL A | 75,000 | $920.0K | 0.4% | +75,000 | New | History |
| Bellus Health Inc New07987C204 | COM NEW | 300,000 | $933.0K | 0.4% | 00.0% | Unchanged | – |
| NSTGNS Wind Down Co., Inc. | COM | 15,000 | $972.0K | 0.5% | +15,000 | New | History |
| ZYMEZymeworks Inc. | COM | 30,000 | $1.04M | 0.5% | −50,000−62.5% | Reduced | History |
| Cerevel Therapeutics HLDNG I15678U102 | *W EXP 06/09/202 | 72,466 | $1.04M | 0.5% | 00.0% | Unchanged | – |
| PCVXVaxcyte, Inc. | COM | 50,000 | $1.13M | 0.5% | +20,000+66.7% | Added | History |
| BCTG Acquisition Corp05492W103 | COM | 100,000 | $1.14M | 0.5% | 00.0% | Unchanged | – |
| MRSNMersana Therapeutics, Inc. | COM | 85,000 | $1.15M | 0.5% | 00.0% | Unchanged | History |
| CGEMCullinan Therapeutics, Inc. | COM | 45,000 | $1.16M | 0.6% | +45,000 | New | History |
| KALVKalVista Pharmaceuticals, Inc. | COM | 50,000 | $1.20M | 0.6% | −50,000−50.0% | Reduced | History |
| AFIBAcutus Medical, Inc. | COM | 80,000 | $1.36M | 0.6% | +20,000+33.3% | Added | History |
| CYTKCytokinetics Inc | COM NEW | 70,000 | $1.39M | 0.7% | +30,000+75.0% | Added | History |
| LKFTLakefront Biotherapeutics NV | SPON ADR | 20,000 | $1.39M | 0.7% | +7,500+60.0% | Added | History |
| BFLYButterfly Network, Inc. | COM CL A | 100,000 | $1.45M | 0.7% | 00.0% | Unchanged | History |
| CNTACentessa Pharmaceuticals plc | SPONSORED ADS | 66,957 | $1.49M | 0.7% | +66,957 | New | History |
| SNCEScience 37 Holdings, Inc. | COM | 150,000 | $1.50M | 0.7% | −250,000−62.5% | Reduced | History |
| Gossamer Bio, Inc.38341PAA0 | NOTE 5.000% 6/0 | – | $1.60M | 0.8% | – | New | – |
| NTLAIntellia Therapeutics, Inc. | COM | 10,000 | $1.62M | 0.8% | +10,000 | New | History |
| CLDXCelldex Therapeutics, Inc. | COM NEW | 50,000 | $1.67M | 0.8% | −80,000−61.5% | Reduced | History |
| AXSMAxsome Therapeutics, Inc. | COM | 25,000 | $1.69M | 0.8% | +15,000+150.0% | Added | History |
| ESTAEstablishment Labs Holdings Inc. | COM | 20,000 | $1.75M | 0.8% | +10,000+100.0% | Added | History |
| SDGRSchrodinger, Inc. | COM | 25,000 | $1.89M | 0.9% | +25,000 | New | History |
| EPIXESSA Pharma Inc. | COM NEW | 70,000 | $2.00M | 1.0% | −20,000−22.2% | Reduced | History |
| SWTXSpringWorks Therapeutics, Inc. | COM | 25,000 | $2.06M | 1.0% | −2,000−7.4% | Reduced | History |
| MREOMereo BioPharma Group plc | SPON ADS | 650,000 | $2.06M | 1.0% | −250,000−27.8% | Reduced | History |
| MGNXMacrogenics Inc | COM | 80,000 | $2.15M | 1.0% | +55,000+220.0% | Added | History |
| Bio Green Med Solution, Inc.23254L603 | COM | 380,000 | $2.25M | 1.1% | 00.0% | Unchanged | – |
| ALDXAldeyra Therapeutics, Inc. | COM | 200,000 | $2.27M | 1.1% | −100,000−33.3% | Reduced | History |
| HZNPHorizon Therapeutics Public Ltd Co | SHS | 25,000 | $2.34M | 1.1% | −10,000−28.6% | Reduced | History |
| IOVAIovance Biotherapeutics, Inc. | COM | 100,000 | $2.60M | 1.2% | +75,400+306.5% | Added | History |
| ASNDAscendis Pharma A/S | SPONSORED ADR | 20,000 | $2.63M | 1.3% | 00.0% | Unchanged | History |
| LUNGPulmonx Corp | COM | 60,000 | $2.65M | 1.3% | +15,000+33.3% | Added | History |
| KDNYChinook Therapeutics, Inc. | COM | 200,000 | $2.82M | 1.3% | +25,000+14.3% | Added | History |
| Medicus Sciences AcquisitionG5960S108 | CL A SHS | 300,000 | $2.90M | 1.4% | +300,000 | New | – |
| OBIOOrchestra BioMed Holdings, Inc. | ORD SHS | 300,000 | $3.06M | 1.5% | +75,000+33.3% | Added | History |
| OCULOcular Therapeutix, Inc | COM | 250,000 | $3.54M | 1.7% | +22,500+9.9% | Added | History |
| ACRSAclaris Therapeutics, Inc. | COM | 275,000 | $4.83M | 2.3% | +52,733+23.7% | Added | History |
| CERECerevel Therapeutics Holdings, Inc. | COM | 200,000 | $5.12M | 2.4% | −70,000−25.9% | Reduced | History |
| CRISCuris Inc | COM NEW | 650,000 | $5.25M | 2.5% | −350,000−35.0% | Reduced | History |
| RCKTRocket Pharmaceuticals, Inc. | COM | 120,000 | $5.32M | 2.5% | +35,000+41.2% | Added | History |
| Retrophin Inc761299AB2 | NOTE 2.500% 9/1 | – | $5.99M | 2.9% | – | – | – |
| PTGXProtagonist Therapeutics, Inc | COM | 140,100 | $6.29M | 3.0% | +90,100+180.2% | Added | History |
| XLRNAcceleron Pharma Inc | COM | 55,000 | $6.90M | 3.3% | +10,000+22.2% | Added | History |
| ARYDARYA Sciences Acquisition Corp IV | CL A | 700,000 | $7.50M | 3.6% | 00.0% | Unchanged | History |
| ZNTLZentalis Pharmaceuticals, Inc. | COM | 142,418 | $7.58M | 3.6% | +64,918+83.8% | Added | History |
| NARIInari Medical, Inc. | Stock | 85,000 | $7.93M | 3.8% | +35,000+70.0% | Added | History |
| KURAKura Oncology, Inc. | COM | 425,000 | $8.86M | 4.2% | +60,000+16.4% | Added | History |
| NAUTNautilus Biotechnology, Inc. | COM | 900,000 | $9.09M | 4.3% | +900,000 | New | History |
| VINCVincerx Pharma, Inc. | COM NEW | 838,311 | $10.9M | 5.2% | +295,301+54.4% | Added | History |
| MORFMorphic Holding, Inc. | COM | 246,201 | $14.1M | 6.7% | +51,201+26.3% | Added | History |
| BBIOBridgeBio Pharma, Inc. | COM | 550,000 | $33.5M | 16.0% | −27,500−4.8% | Reduced | History |
Options (7)
Puts and calls in the same filing. Amounts are the market value of the underlying shares, which is what 13F reports.
| Security | Class | Puts | Calls |
|---|---|---|---|
| State Street SPDR S&P Biotech ETF78464A870 | ETF | $27.1M | – |
| ARK ETF Tr00214Q302 | GENOMIC REV ETF | $20.8M | – |
| Curevac N VN2451R105 | COM | $11.0M | – |
| ALNYAlnylam Pharmaceuticals, Inc. | COM | – | $4.24M |
| IONSIonis Pharmaceuticals Inc | COM | – | $2.99M |
| MRNAModerna, Inc. | Stock | – | $2.94M |
| IMVTImmunovant, Inc. | COM | – | $317.0K |
Sold out since Q1 2021 (14)
Positions held at the end of Q1 2021 that are gone from this filing.
| Security | Class | Shares in Q1 2021 | Value in Q1 2021 | % of portfolio in Q1 2021 | History |
|---|---|---|---|---|---|
| Arya Sciences Acquisition CoG3166W106 | COM CL A | 689,000 | $9.49M | 4.7% | – |
| TVTXTravere Therapeutics, Inc. | COM | 220,000 | $5.49M | 2.7% | History |
| Medicus Sciences AcquisitionG5960S116 | UNIT 99/99/9999 | 300,000 | $2.96M | 1.4% | – |
| STROSutro Biopharma, Inc. | COM | 80,000 | $1.82M | 0.9% | History |
| Highcape Cap Acquisition Cor42984L105 | COM CL A | 150,000 | $1.79M | 0.9% | – |
| Vincerx Pharma, Inc.92731L114 | *W EXP 12/24/202 | 218,000 | $881.0K | 0.4% | – |
| CCCCC4 Therapeutics, Inc. | COM STK | 20,000 | $740.0K | 0.4% | History |
| Aslan Pharmaceuticals Ltd04522R101 | ADS | 200,000 | $670.0K | 0.3% | – |
| XFORX4 Pharmaceuticals, Inc | COM | 75,000 | $646.0K | 0.3% | History |
| BYSIBeyondSpring Inc. | SHS | 50,000 | $554.0K | 0.3% | History |
| EPZMEpizyme, Inc. | COM | 50,000 | $436.0K | 0.2% | History |
| WINTWindtree Therapeutics Inc | COM | 42,847 | $105.0K | 0.1% | History |
| Vesper Healthcare Acqstn Cor92538T112 | *W EXP 09/30/202 | 45,000 | $94.0K | <0.1% | – |
| ZYNEZynerba Pharmaceuticals, Inc. | COM | 13,285 | $62.0K | <0.1% | History |